

Supplementary material

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Castro, L., Pereira, A., & Ribeiro, N. (2021). The Body mass index in patients with Multiple Sclerosis: A meta-analysis. *Journal of Statistics on Health Decision*, 3(1), 99-104. <https://doi.org/10.34624/jshd.v3i1.24946> ; published online July 22, 2021.

The Body mass index in patients with Multiple Sclerosis: A meta-analysis.

Appendix

Tables:

Table A1: Characteristics of the studies included in the meta-analysis of the mean BMI in patients with MS. The green data has been added by us.

Authors	Year	Country	Region	MS_N	MS_Age	MS_% Female	MS_BMI	MS_SD BMI	MS_EDSS	C_N	C_Age	C_% Female	C_BMI	C_SD BMI
Hassanpour	2020	Iran	Developing	20	40,1	55	24,23	2,5	NA	20	39,6	50	23,7	1,3
Koskderelioglu	2020	Turkey	Developed	91	38,8	58	25,4	4,6	NA	52	36,6	64	24,7	4
Maric	2020	Servia	Developed	78	41,7	74	24,8	4,5	2	26	45,5	69	24,7	3,7
Abbasi	2019	Iran	Developing	22	37	5	23,13	4,45	1,54	24	38,83	17	24,42	4,3
Ghazavi	2019	Iran	Developing	93	34,62	84	23,46	4,07	NA	94	34,96	81	24,47	3,81
Baynard	2018	USA	Developed	30	47	80	26	5	NA	31	47	81	25,3	4,4
Solmaz	2018	Turkey	Developed	42	41,9	100	24,8	3,9	2,2	41	39,7	100	26,4	4,04
Tong	2018	China	Developed	47	35,0	77,0	22,36	2,95	2,64	30	33,9	73	21,58	2,41
Graves	2018	USA	Developed	415	42,6	100	24,9	5,6	1,5	180	44	100	24,4	4,7
Belov	2018	USA	Developed	193	42,2	67	26,8	5,8	2	193	42,9	67	26,8	5,7
Karimi	2017	Iran	Developing	43	48,6	72	24,8	4,3	3,7	44	44,3	77	26,1	5,1
Oliveira	2017	Brazil	Developing	137	42,68	62	24,68	5,5	3,28	218	35,67	70	25,5	4,54
Yalcinkaya	2016	Turkey	Developed	21	NA	NA	26,3	4,6	3,6	17	NA	NA	27,7	5,2
Shivappa	2016	Iran	Developing	68	30,4	84	25,1	5	NA	140	30,6	81	24,2	4,4
Klaren	2016	USA	Developed	162	44,5	87	27,9	7,3	2	80	44,1	91	26,6	6,1
Kallaur	2016	Brazil	Developing	108	40,1	70	25,2	5,1	NA	249	36,7	71	25,1	4,4
Bhargava	2016	USA	Developed	27	40,2	100,0	25,3	2,9	NA	30	37,9	100	23,6	2,9
Moccia	2015	Italy	Developed	265	42,2	62	26,3	4,5	3,8	530	42,9	62	26,6	4,9
Keményová	2015	Slovakia	Developed	46	37,26	83	22,83	4,51	2,34	31	38,81	23	28,2	2,93
Davis	2014	South Africa	Developing	114	43,5	NA	24,82	1,06	4,15	195	50	NA	26,34	1,47
Ayatollahi	2013	Iran	Developing	51	36	88	23,5	2,3	3	407	36,5	100	23,6	2,3
Messina	2013	USA	Developed	45	51,1	78	29,19	6,02	4,3	48	45,1	71	26	6,2
Markianos	2013	Greece	Developed	469	34,5	NA	24,16	4,49	1,8	358	36,4	NA	25,83	4,41
Prosperini	2013	Italy	Developed	100	38,2	64	22,8	3,6	3,2	50	37,6	64	23,1	2,9
Rotondi	2013	Italy	Developed	84	34,8	63	23,76	4,32	2,55	50	39,4	64	24,79	2
Kraszula	2012	Poland	Developed	25	40,3	64	23,7	0,6	3,5	25	38,5	64	24,25	0,3
Kaminska	2012	Canada	Developed	62	47,3	73	26	5,1	3,6	32	46,5	63	25,9	6,8
Sioka	2011	Greece	Developed	69	39	NA	24,8	4,2	2,13	81	38,7	NA	25,7	4,8
Trojan	2007	Canada	Developed	53	47	64	26,6	4,3	3,4	12	47,4	NA	24,6	4,3
Ghadirian	1998	Canada	Developed	197	39,85	NA	23,34	4,53	NA	202	39,7	NA	24,47	4,61
Formica	1997	USA	Developed	71	45,6	100	23,6	0,6	6,8	71	47,7	100	26	1

Figures captions/legends:




Figure A1: Funnel plot of all studies.




Figure A2: Influence Characteristics plots of all the studies. Blue dots- influential studies; Red dots-atypical studies.




Figure A5: Bubble plot, for region and year of publication.




Figure A6: Baujat plot, for the co variables region and year of publication.